Corporate Magazine 2012 - Boehringer Ingelheim

SPIRIVA®: 10 YEARS AND MORE OF CLINICAL INNOVATION AND COMMITMENT TO COPD PATIENTSGlobal Initiative for ChronicObstructive Lung Disease(GOLD) is formed.spiriva® for the treatment ofCOPD delivered via the Handi-Haler® device is launched inEuropean and Asian countriesspiriva® HandiHaler®receives US FDA approvalDevelopment of tiotropiumbromideforCOPD began.GOLD releases its first report:Global Strategy for theDiagnosis, Management,and Prevention of COPD.International guidelines recommendinhaled long-acting bronchodilatorsas first-line maintenancetherapy for COPD.spiriva® becomes theworld’s most-prescribedCOPD maintenancetreatment.1985 1997 2001 2002 200320042005SPIRIVA®spiriva® is delivered via the Handi-Haler®, a breath-actuated, singledosedry powder inhaler, or byspiriva® respimat® Soft Mistinhaler, a propellant-free, newgeneration inhaler that combinesinnovative technology with theproven efficacy of spiriva®.Over the years, more than 175 clinicaltrials with the active ingredient tiotropiumin COPD have been conductedinvestigating a broad range of patientsin studies of up to four years.spiriva® has an established efficacy andtolerability profile, as demonstrated inmultiple clinical trials and extensivereal-world experience spanning overten years.spiriva® provides proven efficacy in abroad range of COPD patients, rangingfrom maintenance-naïve patients andacross varying severities of airflowlimitation (GOLD 2 to 4) to those patientswith or without concomitant respiratorytherapy, including long-actingbeta-antagonists.Reflected in global COPD guidelinesThe Global Initiative for Chronic ObstructiveLung Disease (GOLD) recognisesthat some of the key goals oftreatment are to alleviate the impactof symptoms, including breathlessness,and reduce the risk of adverse healthevents, such as exacerbations.In its report Global Strategy for Diagnosis,Management, and Prevention ofCOPD from 2011, GOLD extensivelyrevised the COPD assessment aspectswith the addition of the individualisedevaluation of symptoms and exacerbationrisk. This assessment now not onlyincludes spirometry tests but also acombination of a patient’s severity ofsymptoms and a history of exacerbations.The 2011 GOLD report recommendslong-acting anticholinergics such asspiriva® for every patient requiringmaintenance therapy (first choice for patientgroups B – D and second option forpatient group A) . This recommendationwas solely based on data for the longactinganticholinergic spiriva®. The recent2013 update of the GOLD’s GlobalStrategy for the Diagnosis, Management,and Prevention of COPD, reflects thesame choice recommendations on theuse of long-acting anticholinergics asproposed in the 2011 GOLD Report.80Boehringer Ingelheim annual report 2012